2 results
Approved WMOCompleted
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Approved WMORecruiting
Primary Objective (Randomized Controlled Trial [RCT] Cohort): to evaluate the efficacy of renal denervation by alcohol-mediated neurolysis using the Peregrine Kits in uncontrolled hypertensive subjects when used in combination with antihypertensive…